A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Efficacy and Safety of LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension.

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Efficacy and Safety of LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 May 2012

At a glance

  • Drugs Eplerenone; LFF 269
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 May 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 May 2012 Actual patient number added 19 according to ClinicalTrials.gov.
    • 16 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top